Hormonal
GLP-1 receptor agonists are an acceptable adjunct to progestin therapy for fertility preservation in young patients with endometrial cancer or atypical hyperplasia, provided they are framed as medically indicated treatment for cancer and fertility rather than cosmetic weight loss.
If you are a young woman with endometrial cancer or atypical hyperplasia and want to preserve fertility, GLP-1 medications like Semaglutide or Tirzepatide can be a helpful tool alongside progestin therapy. However, you must have a clear, honest conversation with your doctor about the costs, potential side effects, and a plan to keep the weight off after stopping the drug. Framing the medication as a medical treatment for your cancer and fertility, rather than just for weight loss, can help you feel more comfortable and less stigmatized.
Weight-loss medication may be an acceptable adjunct to progestin treatment in this population, if preceded by a thorough risk–benefit discussion and early counselling on the role and management of obesity in EC/AH.
Why this rating
Qualitative study of patient acceptability (N=13), not a clinical efficacy trial.
Source
Acceptance of weight loss medication in patients with atypical hyperplasia or carcinoma of the endometrium as part of the fertility preservation treatment: A qualitative study
Oluwanifemi O. Adeoye et al. · Gynecologic Oncology Reports · 2026
DOI 10.1016/j.gore.2026.102058
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →